IDO2 and peritoneal carcinoma: A new clinical trial is recruiting patients with recurrent ovarian and fallopian tube cancer along with other primary peritoneal carcinomas, for a phase1 study looking at the effect of in vivo suppression of T cells by using an indoleamine 2,3-dioxygenase (IDO) inhibitor, along with IP delivery of haploidentical NK cells (Clinicaltrials.gov identifier: NCT02118285).